SHANGHAI, China, September 29, 2022 - Ping An-Shionogi Co., Ltd. (Head Office: Shanghai, China; Chairman and CEO: Tatsumori Yoshida) today announced that the parent company, Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter "Shionogi"), announced the achievement of the primary endpoint for Ensitrelvir Fumaric Acid (S-217622) in the Phase 3 part of the Phase 2/3 clinical trial in Asia. Please refer to the original press release by Shionogi for details.
Original press release